0.6412
전일 마감가:
$0.6602
열려 있는:
$0.669
하루 거래량:
762.86K
Relative Volume:
1.46
시가총액:
$32.93M
수익:
$107.88M
순이익/손실:
$-33.52M
주가수익비율:
-0.9559
EPS:
-0.6708
순현금흐름:
$-11.94M
1주 성능:
-18.84%
1개월 성능:
-68.87%
6개월 성능:
-81.52%
1년 성능:
-70.85%
Mdxhealth Sa Stock (MDXH) Company Profile
Compare MDXH vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
MDXH
Mdxhealth Sa
|
0.6412 | 33.91M | 107.88M | -33.52M | -11.94M | -0.6708 |
|
TMO
Thermo Fisher Scientific Inc
|
482.08 | 183.60B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
176.11 | 127.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
550.82 | 44.71B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
135.05 | 38.38B | 7.23B | 1.41B | 1.09B | 4.979 |
|
WAT
Waters Corp
|
371.93 | 37.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Mdxhealth Sa Stock (MDXH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-17 | 개시 | Craig Hallum | Buy |
| 2024-10-31 | 개시 | Lake Street | Buy |
| 2023-05-31 | 개시 | TD Cowen | Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Mdxhealth Sa 주식(MDXH)의 최신 뉴스
MDxHealth (MDXH) Edges Higher as Stock Tests Key Resistance Near $0.80Sentiment Shift - thelegaladvocate.com
MDxHealth (MDXH) VP Brendan O’Connell files initial Form 3 ownership report - Stock Titan
MDxHealth (MDXH) Slides 6.25% as Cancer Diagnostics Stock Tests Key Support LevelEnding Diagonal - thelegaladvocate.com
MDxHealth to Shut Down Resolve UTI Business - Orange County Business Journal
MDXHealth Q1 2026 Earnings: EPS Miss Weighs on Shares as Company Navigates Diagnostic MarketEarnings Call Transcript - thelegaladvocate.com
MDxHealth SA (MDXH) Stock Analysis: -3.98% Loss — Key Levels 2026-05-21Fair Value Gap - Newser
Mdxhealth Refocuses on Prostate Franchise Amid Headwinds - The Globe and Mail
MDxHealth SA (MDXH) Stock Analysis: +4.85% Gain — What to Watch 2026-05-20Upthrust Pattern - Newser
Earnings call transcript: MDxHealth Q1 2026 sees significant stock drop amid earnings miss - Investing.com Canada
MDxHealth SA (MDXH) Slips -1.62%, Testing $0.84 Support 2026-05-18Verified Signals - Newser
MDxHealth SA (MDXH) Q1 2026 Earnings: Miss Sparks ConcernCrowd Trend Signals - Newser
MDxHealth SA (MDXH) Q1 2026 Results Fall Short — EPS $-0.17, Revenue $N/ADividend Cut Risk - Newser
MDxHealth SA stock (US55278X1072): cancer diagnostics specialist back in focus after capital raise - AD HOC NEWS
MDxHealth SA (MDXH) Q1 2026 Earnings Miss: EPS $-0.19 vs $-0.15 Expected - Newser
MDxHealth Exits UTI Business Amid Medicare Reimbursement Dispute - HarianBasis.co
MDxHealth S.A. (NASDAQ:MDXH) Q1 2026 Earnings Call Transcript - Insider Monkey
MDxHealth (MDXH) Q1 Loss Near US$8.9 Million Reinforces Bearish Profitability Concerns - simplywall.st
MDXH Sets New Revenue Forecast Excluding Resolve, Anticipates St - GuruFocus
MDXH Maintained by Lake Street -- Price Target Lowered to $5.00 - GuruFocus
Mdxhealth Earnings Call: Prostate Pivot Amid Pressure - TipRanks
MDXH Maintained by TD Cowen -- Price Target Lowered to $1.50 - GuruFocus
MDXH Faces Challenges Amid Strategic Revisions and Medicare Disp - GuruFocus
MDxHealth SA Stock 12‑Month Price Target Cut to $3.9, Implies 100% Upside - TradingView
MDxHealth to exit the Resolve mdx business - TipRanks
MDxHealth price target lowered to $4 from $7 at BTIG - TipRanks
MDxHealth SA Stock 12‑Month Price Target Cut to $4.7, Implies 141% Upside - TradingView
TD Cowen cuts MDxHealth stock price target on Medicare dispute By Investing.com - Investing.com Australia
TD Cowen cuts MDxHealth stock price target on Medicare dispute - Investing.com
MDXH Maintained by BTIG -- Price Target Lowered to $4.00 - GuruFocus
Dow Jumps Over 250 Points; US Retail Sales Increase In April - Benzinga
MDxHealth SA stock (US55278X1072): Strong Q1 results amid strategic shift - AD HOC NEWS
MDxHealth SA Stock 12‑Month Price Target Cut to $5.7, Implies 192% Upside - TradingView
MDxHealth SA Stock 12‑Month Price Target Cut to $6.8, Implies 249% Upside - TradingView
MDxHealth SA (MDXH) Q1 2026 Earnings Call Highlights: Revenue Su - GuruFocus
MDxHealth Q1 Earnings Call Highlights - Inkl
Mdxhealth exits Texas Resolve lab after $10.4M Medicare recoupment - Stock Titan
MDXH Reports Strong Q1 Results Amid Strategic Business Changes - GuruFocus
MDXH: Exited UTI business, focusing on AI-driven prostate cancer diagnostics with 20–26% growth outlook - TradingView
MDXH: Exited UTI business, core cancer revenue up 11%, 2026 guidance set at $110–$115 million - TradingView
Earnings call transcript: MDxHealth Q1 2026 results miss forecasts, stock steady - Investing.com
Earnings call transcript: MDxHealth Q1 2026 results miss forecasts, stock steady By Investing.com - Investing.com South Africa
Mdxhealth Exits Resolve Business, Refocuses on Prostate Cancer as Q1 2026 Revenue Rises 13% - TipRanks
MDxHealth Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Mdxhealth reports Q1-2026 results - marketscreener.com
MDxHealth (NASDAQ: MDXH) posts Q1 2026 growth and issues new 2026 guidance - Stock Titan
Mdxhealth Reports Q1-2026 Results - The Manila Times
MDxHealth reports Q1 EPS (17c) vs. (19c) last year - TipRanks
Mdxhealth Sa (MDXH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):